GRI Bio (NASDAQ:GRI) Price Target Raised to $36.00 at Ascendiant Capital Markets

GRI Bio (NASDAQ:GRI) had its target price raised by Ascendiant Capital Markets from $35.00 to $36.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of GRI Bio in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, GRI Bio currently has an average rating of “Hold” and a consensus target price of $23.00.

GRI Bio Stock Performance

GRI Bio stock opened at $2.06 on Monday. GRI Bio has a fifty-two week low of $1.10 and a fifty-two week high of $16.92. The stock’s 50 day simple moving average is $1.91 and its two-hundred day simple moving average is $1.67. The stock has a market cap of $6.73 million, a price-to-earnings ratio of -0.25 and a beta of -1.48.

GRI Bio (NASDAQ:GRI) last announced its earnings results on Friday, November 14th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.17). On average, analysts predict that GRI Bio will post -3.04 earnings per share for the current year.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.